Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant

计划入组 16 人 · 首次发布于 2007 年 2 月 13 日

A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

计划入组 44 人 · 首次发布于 2010 年 2 月 17 日

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

计划入组 9 人 · 首次发布于 2007 年 6 月 22 日

Zemab

Rebmab 100

Rebmab-200

BEHMAN HOSPITAL

Egypt

JONATHAN BERMAN

United States

GENMAB K.K.

Japan

Faron Pharmaceuticals Completes Enrollment in BEXMAB Phase II MDS Trial

Faron Pharmaceuticals' Bexmarilimab Shows Promise in Myelodysplastic Syndrome Treatment

Faron Pharma's Bexmarilimab Receives UK Fast-Track Status for Myelodysplastic Syndrome Treatment